Dr. Leland Metheny, MD
Claim this profileUniversity Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center
Studies Leukemia
Studies Multiple Myeloma
10 reported clinical trials
20 drugs studied
Area of expertise
1Leukemia
CD22 positive
HLA positive
HLA negative
2Multiple Myeloma
Stage I
Stage II
Affiliated Hospitals
Clinical Trials Leland Metheny, MD is currently running
Inotuzumab Ozogamicin Post-Transplant
for Leukemia and Lymphoma
This study has two phases, Phase I and Phase II. The main goal of the Phase I portion of this research study is to see what doses post-transplant inotuzumab ozogamicin can safely be given to subjects without having too many side effects. The Phase II portion of this study is to see what side effects are seen with medication after transplant. Inotuzumab ozogamicin is a combination of an antibody and chemotherapy which has been shown to have significant activity against relapsed/refractory acute lymphocytic leukemia (ALL). Inotuzumab ozogamicin is considered experimental in this study.
Recruiting1 award Phase 1 & 2
Combination Therapy
for Multiple Myeloma
This phase III trial compares the combination of four drugs (daratumumab, bortezomib, lenalidomide and dexamethasone) to the use of a three drug combination (daratumumab, lenalidomide and dexamethasone). Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Chemotherapy drugs, such as lenalidomide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Daratumumab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Anti-inflammatory drugs, such as dexamethasone lower the body's immune response and are used with other drugs in the treatment of some types of cancer. Adding bortezomib to daratumumab, lenalidomide, and dexamethasone may be more effective in shrinking the cancer or preventing it from returning, compared to continuing on daratumumab, lenalidomide, and dexamethasone.
Recruiting2 awards Phase 332 criteria
More about Leland Metheny, MD
Clinical Trial Related7 years of experience running clinical trials · Led 10 trials as a Principal Investigator · 6 Active Clinical TrialsTreatments Leland Metheny, MD has experience with
- Lenalidomide
- Donor Search Prognosis Score
- Autologous CAR-T Cell Therapy Expressing The BAFF-ligand
- BAFF CAR-T
- O6-benzylguanine
- P140K-MGMT
Breakdown of trials Leland Metheny, MD has run
Leukemia
Multiple Myeloma
Plasma Cell Neoplasms
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Leland Metheny, MD specialize in?
Leland Metheny, MD focuses on Leukemia and Multiple Myeloma. In particular, much of their work with Leukemia has involved CD22 positive patients, or patients who are HLA positive.
Is Leland Metheny, MD currently recruiting for clinical trials?
Yes, Leland Metheny, MD is currently recruiting for 6 clinical trials in Cleveland Ohio. If you're interested in participating, you should apply.
Are there any treatments that Leland Metheny, MD has studied deeply?
Yes, Leland Metheny, MD has studied treatments such as Lenalidomide, Donor Search Prognosis Score, Autologous CAR-T cell therapy expressing the BAFF-ligand.
What is the best way to schedule an appointment with Leland Metheny, MD?
Apply for one of the trials that Leland Metheny, MD is conducting.
What is the office address of Leland Metheny, MD?
The office of Leland Metheny, MD is located at: University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center, Cleveland, Ohio 44106-5065 United States. This is the address for their practice at the University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.